920. A Phase 2 Multi-Center, Prospective, Randomized, Double-Blind Study to Assess the Clinical and Antiviral Efficacy and Safety of Nitazoxanide for the Treatment of Norovirus in Hematopoietic Stem Cell and Solid Organ Transplant Recipients
C Boutin(Centre Hospitalier de l’Université de Montréal), Robin K. Avery(Johns Hopkins University), Michael D. Green(University of Pittsburgh), M. Hong Nguyen(University of Pittsburgh), Diana F. Florescu(University of Nebraska Medical Center), Michael Angarone(Northwestern University), Ajit P. Limaye(University of Washington), Laurie Keefer(Icahn School of Medicine at Mount Sinai), Steven A. Pergam(Seattle Cancer Care Alliance), Daniel Kaul(University of Michigan), Pearlie P. Chong(The University of Texas Southwestern Medical Center), Michael G. Ison(MDA Engineering (United States)), Marian G. Michaels(University of Pittsburgh), Amna Daud(Northwestern University), Lara Danziger‐Isakov(Cincinnati Children's Hospital Medical Center), Cynthia E. Fisher(University of Washington), Michelle Callegari(Northwestern University), Lisa Clough(University of Kansas Medical Center)
Cited by 2
Related Papers
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Development and Validation of the Rome IV Diagnostic Questionnaire for Adults
|Gastroenterology|2016|696
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
|JAMA|2021|536
Baboon-to-human liver transplantation
|The Lancet|1993|469
Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|452